By analyzing existing basic indicators between ProQR Therapeutics and Apple, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Apple with a short position in ProQR Therapeutics. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ProQR Therapeutics has an asset utilization ratio of 0.65 percent. This connotes that the company is making $0.006461 for each dollar of assets. An increasing asset utilization means that ProQR Therapeutics BV is more efficient with each dollar of assets it utilizes for everyday operations.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in ProQR Therapeutics. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its
performance over time. Several factors influence the investment perspective on ProQR Therapeutics, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.
How important is ProQR Therapeutics's Liquidity
ProQR Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance ProQR Therapeutics BV ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. ProQR Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to ProQR Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of ProQR Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between ProQR Therapeutics's total debt and its cash.
ProQR Therapeutics Gross Profit
ProQR Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing ProQR Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show ProQR Therapeutics Gross Profit growth over the last 10 years. Please check ProQR Therapeutics'
gross profit and other
fundamental indicators for more details.
A Deeper Analysis
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Now, let's check ProQR Therapeutics revenue. Based on the latest financial disclosure, ProQR Therapeutics BV reported 1.35
M of revenue. This is 99.98% lower than that of the Biotechnology sector and 99.82% lower than that of the
Health Care industry. The revenue for all United States stocks is 99.99% higher than that of ProQR Therapeutics. As for Apple we see revenue of 394.33
B, which is much higher than that of the Health Care
| PRQR | 1.35 Million | 3.43E-4 |
| Sector | 742.91 Million | 0.19 |
| AAPL | 394.33 Billion | 99.81 |
ProQR Therapeutics possible relapse in January
Latest skewness is at 4.83. ProQR Therapeutics BV is displaying above-average volatility over the selected time horizon. Investors should scrutinize ProQR Therapeutics BV independently to ensure intended market timing strategies are aligned with expectations about ProQR Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ProQR Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ProQR Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Takeaway on ProQR Therapeutics Investment
While other entities under the biotechnology industry are still a bit expensive, ProQR Therapeutics may offer a potential longer-term growth to retail investors. On the whole, as of the 28th of December 2022, our research shows that ProQR Therapeutics is a rather very risky investment opportunity with a
low chance of financial distress in the next two years. From a slightly different view, the entity currently appears to be
undervalued. Our final 90 days buy-sell recommendation on the enterprise is
Strong Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of ProQR Therapeutics BV. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
